UNSPSC 51281519: Delamanid

Delamanid (USAN, INN) is a drug for the treatment of multi-drug-resistant tuberculosis. It works by blocking the synthesis of mycolic acids in Mycobacterium tuberculosis, the organism which causes tuberculosis, thus destabilising its cell wall. The drug is approved in the EU under the trade name Deltyba (made by Otsuka Pharmaceutical).

UNSPSC 51281519 Delamanid, a Commodity code, nominally identifies a specific tuberculosis drug, but recent state and local opportunities show the code being used to tag broader pharmaceutical procurement — antibiotic tablets, opioid-reversal agents, and drug deactivation systems — rather than delamanid itself. State and local buyers use this Commodity code to classify pharmaceutical warehouse orders, emergency medical supplies, and public health inventory acquisitions sourced through piggyback contracts, cooperative purchasing agreements, and competitive bidding. Issuing bodies include state health departments and county governments pursuing fixed-price pharmaceutical supply agreements, often with quarterly or annual delivery schedules and multi-year renewal options.

Activity is sparse and geographically scattered. Illinois Department of Public Health awarded a $2,999,999.11 three-year piggyback contract through the MMCAP Infuse consortium to Chartwell Rx LLC in August 2026 for antibiotic tablets (Doxycycline Hyclate 100mg and Ciprofloxacin Hydrochloride 500mg) under an Invitation for Bid process. Seminole County, Florida issued an IFB in June 2026 seeking 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with a July 26 response deadline, a two-year initial term with one-year renewal option, and quarterly delivery to the Seminole County Community Health Building in Sanford. The code shows minimal recent volume and no clear pattern of repeat buyers or concentrated geographic demand.